NervGen Pharma Corp. Common stock cash flow to debt ratio of -232.99K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

NervGen Pharma Corp. Common stock's free cash flow has decreased 15.86% from $-16.83M last year to $-19.50M, signaling decreasing performance

NervGen Pharma Corp. Common stock's debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

NervGen Pharma Corp. Common stock's debt has decreased relative to shareholder equity from 0.04 last year to 0.00 today, signaling strengthened financials

NervGen Pharma Corp. Common stock has negative EBITDA, making leverage ratio unreliable

NervGen Pharma Corp. Common stock earns at least as much interest as it pays. Interest obligations are fully covered.

NervGen Pharma Corp. Common stock has insufficient data to evaluate this check.

NervGen Pharma Corp. Common stock's short-term assets of $22.80M exceed its short-term liabilities of $19.73M

NervGen Pharma Corp. Common stock's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

NervGen Pharma Corp. Common stock's return on equity of -17.54K%, is lower than 15.00%, indicating bad performance

NervGen Pharma Corp. Common stock's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

NervGen Pharma Corp. Common stock had positive net income in only 0.00 out of 5 years, indicating unstable earnings

NervGen Pharma Corp. Common stock has negative free cash flow, indicating the company is burning cash rather than generating it

NervGen Pharma Corp. Common stock has negative free cash flow, indicating cash burn

NervGen Pharma Corp. Common stock's yearly earnings has decreased 83.90% since last year from $-23.99M to $-44.12M, signaling decreasing performance

NervGen Pharma Corp. Common stock's yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -719.57% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

NervGen Pharma Corp. Common stock has insufficient revenue history to calculate 3-year revenue CAGR.

NervGen Pharma Corp. Common stock had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance

NervGen Pharma Corp. Common stock had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

NervGen Pharma Corp. Common stock has insufficient data to evaluate this check.

NervGen Pharma Corp. Common stock has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

NervGen Pharma Corp. Common stock is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

NervGen Pharma Corp. Common stock has negative or missing EBITDA, making EV/EBITDA ratio unreliable

NervGen Pharma Corp. Common stock has insufficient data to evaluate this check.

NervGen Pharma Corp. Common stock has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

NervGen Pharma Corp. Common stock has a price-to-book ratio of 108.37x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

NervGen Pharma Corp. Common stock has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue